Cargando…

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to...

Descripción completa

Detalles Bibliográficos
Autor principal: Ram, C Venkata S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104608/
https://www.ncbi.nlm.nih.gov/pubmed/21633521
http://dx.doi.org/10.2147/VHRM.S15787
_version_ 1782204625812717568
author Ram, C Venkata S
author_facet Ram, C Venkata S
author_sort Ram, C Venkata S
collection PubMed
description Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability profile with similar renoprotective properties compared with ramipril, suggesting a potential clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in cardioprotection and renoprotection for high-risk patients.
format Text
id pubmed-3104608
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31046082011-06-01 Reappraisal of role of angiotensin receptor blockers in cardiovascular protection Ram, C Venkata S Vasc Health Risk Manag Review Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability profile with similar renoprotective properties compared with ramipril, suggesting a potential clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in cardioprotection and renoprotection for high-risk patients. Dove Medical Press 2011 2011-05-15 /pmc/articles/PMC3104608/ /pubmed/21633521 http://dx.doi.org/10.2147/VHRM.S15787 Text en © 2011 Ram, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ram, C Venkata S
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title_full Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title_fullStr Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title_full_unstemmed Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title_short Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
title_sort reappraisal of role of angiotensin receptor blockers in cardiovascular protection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104608/
https://www.ncbi.nlm.nih.gov/pubmed/21633521
http://dx.doi.org/10.2147/VHRM.S15787
work_keys_str_mv AT ramcvenkatas reappraisalofroleofangiotensinreceptorblockersincardiovascularprotection